Introduction
It is reasoned that steroid sulfatase (STS) has a significant role in fueling the growth and development of hormone-dependent diseases, since the enzyme hydrolyses biologically inactive steroid sulfates back to their active unconjugated forms. In hormone-dependent breast cancer for example, STS is responsible for the conversion of estrone sulfate (E1S) to estrone (E1) and also dehydroepiandrosterone sulfate (DHEA-S) to DHEA. The formation of DHEA by the STS pathway constitutes the production of 90% of androstenediol which is an estrogen (ca. 100-fold weaker than estradiol), despite structurally being classified as an androgen [1] [2] [3] [4] . On this basis, the inhibition of STS in this type of cancer might lead to estrogen deprivation and hence render therapeutic intervention in the malignancy.
Once STS had been identified as a target for delivering a potential new form of endocrine therapy, considerable attention was placed on designing inhibitors of this enzyme over the past two decades. One approach was to replace the sulfate group (OSO 3 -) of E1S with other sulfate surrogates or mimics that are not metabolically labile or hydrolysable by the enzyme in the course of competing with E1S for binding to the enzyme active site [5] [6] [7] [8] [9] . Despite the large number of compounds that have been explored in this category, none of these compounds was deemed to be potent enough or adequately attractive pharmaceutically for further development as an inhibitor of STS. The breakthrough in the design of potent STS inhibitors came when the sulfate group of E1S was replaced by a sulfamate moiety (-OSO 2 NH 2 ).
10 Estrone 3-O-sulfamate (EMATE) ( Fig. 1 ) was found to be a highly potent inhibitor with an IC 50 of 18 nM in a human placental microsomes preparation. 11 More exceptionally, EMATE inhibits STS in a time-and concentration-dependent manner, indicating that the mechanism Scheme 1. Nitration of estrone to give predominately 2-nitroestrone (1a) and 4-nitroestrone (2a) which upon sulfamoylation gave their respective sulfamates (1) and (2) . a) conc. HNO 3 /glacial acetic acid, [70] [71] [72] [73] [74] [75] o C to r.t.; b) NaH/DMF, H 2 NSO 2 Cl, 0 o C.
of action is of an irreversible nature. EMATE is orally active in vivo. In one study, 12 administration at 10mg/kg inhibited rat liver STS activity almost completely (99%) when given by the oral or subcutaneous route and the inhibition persisted (>95%) for up to 7 days after a single dosing. However, EMATE was unexpectedly shown to be more estrogenic than ethinylestradiol when administered orally in rats 13 , although it was revealed subsequently that estrogen sulfamates per se do not bind to the estrogen receptor 14 . A follow-up study demonstrated that STS has a crucial role in regulating the estrogenicity associated with EMATE as its estrogenicity is abolished when STS is inhibited by co-administration of the non-estrogenic STS inhibitor Irosustat (STX64, Fig. 1 ) 15 . Nonetheless, this unwanted estrogenic property rendered the inhibitor undesirable for use as an anti-endocrine agent for hormone-dependent cancers. However, a congener of EMATE, estradiol 3-O-sulfamate, entered human clinical trials in the late 90s as an orally active pro-drug for estradiol and good activity has also been reported in animal models of endometriosis, as an STS inhibitor. 16 As EMATE remains an interesting compound because of its diverse pharmacological properties, we further expand the SAR studies in this work. To this end, we substituted at the 2-and/or 4-position of A-ring with a nitro group, halogens, alkyl groups and a cyano group. The D-ring was modified by removal of the C17 carbonyl group. In addition, three compounds were prepared which can be loosely described as 'cyclic sulfamate' derivatives of EMATE as the N-atom of the sulfamate group of EMATE is bonded to either the 2-or 4-position of the steroid scaffold. The synthesized compounds were tested for STS inhibitory activity in a placental microsomes preparation and also in MCF-7cells.
Chemistry
2-Nitroestrone (1a, Scheme 1) and 4-nitroestrone (2a, Scheme 1) were prepared by nitrating estrone according to the method of Tomson and Horwitz. 17 Compound 2a came out of the reaction mixture overnight and was deposited as a yellow precipitate whereas 1a was isolated from the filtrate and purified by several cycles of recrystallization. An earlier method was employed for the sulfamoylation of these nitrated estrones (Scheme 1). This involved treating a solution of 1a or 2a in anhydrous N,Ndimethylformamide (DMF) with sodium hydride (NaH) followed by addition of a freshly concentrated solution of sulfamoyl chloride in toluene, which was prepared according to the method of Woo et al. 18 The synthesis of 2-and 4-alkylestrone was carried out as described by Patton. 19 A Claisen rearrangement of the intermediate 3-O-(2-propenyl)estrone (3, Scheme 2) to give 2-and 4-(2-propenyl)estrone was straightforward although the separation of the geometrical isomers obtained was particularly cumbersome. 2-(2-Propenyl)estrone (4a, Scheme 2) was only isolated in poor yield upon repeated and slow (over two weeks) fractional recrystallizations of the crude material in diethyl ether. Despite careful fractional recrystallization of the crude 4-(2-propenyl)estrone (5a, Scheme 2), this isomer could not be obtained in a pure state and the best sample in our hands contained approximately 25% of 4a as shown by 1 H NMR. When a mixture of 2-(2-propenyl)-and 4-(2-propenyl)estrones in DMF was heated with 3-bromoprop-1-ene in the presence of NaH, a mixture of the 3-O-(2-propenyl) derivatives of 4a and 5a (6 and 7 respectively, Scheme 2) was obtained. When this mixture was subjected to Claisen rearrangement conditions 2,4-di-(2-propenyl)estrone (8a, Scheme 2) was obtained in good yield. Compounds 4a, 5a and 8a were sulfamoylated in the same manner as 1a to give sulfamates 4, 5 and 8 respectively.
Initially, 2-n-propyl-(9), 4-n-propyl-(10) and 2,4-di-n-propyl-(11) EMATEs were obtained by sulfamoylating the corresponding parent phenols that were obtained upon hydrogenation of the (2-propenyl)estrones. However, it was found subsequently that the sulfamate group is not labile to the hydrogenation conditions employed and hence 2-(2-propenyl)-(4), 4-(2-propenyl)-(5) and 2,4-n-di-(2-propenyl)-(8) EMATEs were hydrogenated directly to give respectively 2-n-propyl-(9) and 4-n-propyl-(10) and 2,4-di-n-propyl-(11) EMATEs (Scheme 3). It is worth noting that while repeated attempts to recrystallize 5 had failed to afford a pure sample other than a batch that was co-recrystallized with 4, pure 10 without contaminating by isomer 9 was obtained when the crude material was recrystallized from ethyl acetate/hexane. Scheme 2. Synthesis of 2-(2-propenyl)estrone 3-O-sulfamate (4), 4-(2-propenyl)estrone 3-O-sulfamate (5) and 2,4-di-(2-propenyl)estrone 3-O-sulfamate (8) via various intermediates (3), (4a), (5a), (6) , (7) and (8a). a) NaH/DMF, 3-bromoprop-1-ene, 80 0 C, 2h; b) N,Ndiethylaniline, N 2 , reflux, 6 h; c) NaH/DMF, H 2 NSO 2 Cl, 0 o C. X = OSO 2 NH 2 * contains ca. 25% of 4a as shown by 1 H NMR; ** impure, contains 6. Scheme 3. Hydrogenation of (2-propenyl)estrone sulfamates (4), (5) and (8) to give respectively 2-n-propylestrone 3-O-sulfamate (9), 4-n-propylestrone 3-O-sulfamate (10) and 2,4-di-npropylestrone 3-O-sulfamate (11). a) Pd-C(10%)/abs. EtOH, H 2 , 50 p.s.i. X = OSO 2 NH 2 * impure Scheme 3. Hydrogenation of (2-propenyl)estrone sulfamates (4), (5) and (8) to give respectively 2-n-propylestrone 3-O-sulfamate (9), 4-n-propylestrone 3-O-sulfamate (10) and 2,4-di-npropylestrone 3-O-sulfamate (11) . a) Pd-C(10%)/absolute EtOH, H 2 , 50 p.s.i. X = OSO 2 NH 2 * impure The route to 2-fluoroestrone 12b (Scheme 4) was described by Page et al. 20 and involved an electrophilic fluorination of estrone by Umemoto's reagent, N-fluoropyridinium triflate, followed by a direct acetylation using acetic anhydride in pyridine in order to facilitate purification of the fluorinated estrone derivative 12a. In our hands, a low yield (12%, after recrystallization) of 12a was obtained from estrone, primarily as a result of competing formation of other by-products (presumably 2-and 4-chloroestrones). Upon deacetylation of 12a using potassium carbonate in methanol, 2-fluoroestrone (12b) was obtained which was purified by preparative TLC (45% yield). Sulfamoylation of 12b with sulfamoyl chloride in the presence of 2,6-di-tert-butyl-4-methylpyridine (DBMP) as base gave 2-fluoroEMATE (12) in 57 % yield.
Several procedures for preparing the 2-chloro, 2-bromo, 2-iodo and 2-cyano derivatives of estrone are available but few of these are regioselective, ie. functionalizing predominantly at position 2. Compounds 15b -18b (Scheme 4) were prepared as described by Page et al. 20 The direct arene thalliation with thallic trifluoroacetate (or triacetate) in trifluoroacetic acid and subsequent displacement of the estrogen-thallium (III) bis(trifluoroacetate) intermediate with copper (I) halides (halides = Cl, Br, I) and copper (I) cyanide gave a convenient regioselective method for the synthesis of 2-substituted estrones. Sulfamoylation of compounds 15b -18b was carried out in a similar manner to 1a to give the sulfamates 15 -18. 21 reported that 4-bromoestrone (19a) was obtained in high yield when a solution of estrone in aqueous acetic acid (contained 15-20% of water) was treated with 5% v/v of bromine in acetic acid in the presence of a small amount of powdered iron. In contrast, when aqueous acetic acid was replaced with glacial acetic acid, the authors reported that the bromination reaction yielded predominately 2-bromoestrone. However, in our hands, 19a was obtained as the main product when a solution of estrone in glacial acetic acid (Scheme 4) was brominated under the conditions used. The sulfamoylation of 19a to give sulfamate 19 was carried out in the same manner as 1a.
Slaunwhite and Neely
The carbonyl group of estrone was reduced to a methylene group under Wolff-Kishner conditions for reduction of steroid ketones. 22 The product 3-hydroxy-1,3,5(10)-estratriene (20a, Scheme 5) was sulfamoylated in the same manner as 1a to give 1,3,5(10)estratriene 3-O-sulfamate (20 obtained by hydrogenating 2-nitro-(1a) and 4-nitroestrone (2a) respectively in the presence of palladium-charcoal. Whilst 23a appears to be stable, decomposition of 21a upon standing and exposure to air at room temperature was observed, as reported by Kraychy, 25 and hence 21a was used without further purification. The selective N-tosylation of 21a and 23a with tosyl chloride to give 2-(21b) and 4-tosylamidoestrone (23b) respectively was carried out in the presence of pyridine using conditions reported by Kurita 26 for the selective N-tosylation of o-aminophenol. Ring closure of 21b and 23b to give the respective cyclic compounds 21c and 23c was carried out with sulfuryl chloride in dichloromethane. Removal of the protecting tosyl group of 21c and 23c with an aqueous solution of potassium fluoride gave 21 and 23 in moderate to good yields. Deprotonation of 21 in DMF with NaH followed by refluxing with methyl iodide gave the Nmethylated derivative 22 We have demonstrated repeatedly in previous work that the STS inhibitory activity of an aryl sulfamate in general can be increased by either placing an electron-withdrawing group adjacent to the sulfamate group, [30] [31] [32] [33] [34] [35] [36] [37] [38] or by having the sulfamate group attached to an aryl ring system such as coumarin, [39] [40] [41] that renders the parent phenol a better leaving group by virtue of lowering its pK a value. With the exception of 1, the same effect is observed for 2, 12, 15 -18 when tested in a placental microsome preparation since these sulfamates were found to be more potent than EMATE as STS inhibitors. A similar trend is observed for STS inhibition in MCF-7 cells with the exception of 17 and 18 which are comparable and slightly weaker inhibitors than EMATE respectively. As shown in Table 2 , the pK a values of various substituted phenols, 2-nitroestrone (1a) and 4-nitroestrone (2a) are between 1 and 3 log units lower than that of an unsubstituted phenol such as estrone. We postulate in general that this lowering of pK a value of the parent phenol improves its leaving group ability which in return facilitates the inactivation of the enzyme by its corresponding sulfamate through sulfamoylation of an essential amino acid residue in the active site. Unexpectedly, 2-nitroEMATE (1) is less potent than EMATE as an STS inhibitor while its congener 4-nitroEMATE (2) is significantly more potent than EMATE despite their parent phenols sharing a similar calculated pK a value of around 7 ( Table  1) . We reason that this result might be due to potential interaction(s) between the nitro group at the 2-position and the sulfamate group at the 3-position in 1, rendering the sulfamate group either less stable chemically and/or less effective in inactivating the enzyme via sulfamoylation. 27 Due to steric hindrance presented by the neighbouring hydrogen atom(s) at C6, the nitro group at the 4-position of 2 might not be amenable to having potential interactions(s) with its sulfamate group at the 3-position, rendering it relatively more stable and effective in sulfamoylating the enzyme. 27 Another possible explanation for the higher STS inhibitory activity observed for 2 is that its 4-nitro group might interact with the enzyme active site favorably. A recent study carried out by Taylor et al. 42 (Table 2) , other factors such as the lipophilicity of compounds might influence the different in vitro activity observed. In general, a more lipophilic inhibitor has a higher affinity for the enzyme active site and hence exhibits better inhibitory activity than one that is less lipophilic. As fluoro derivative 12 is the least lipophilic, whereas iodo derivative 17 is the most lipophilic, one might expect the potency of these 2-halogenated derivatives of EMATE against STS to be in an ascending order from 12 to 17. However, the fact that 17 (IC 50(P.M.) = 6.1 nM and IC 50(MCF-7) = 0.81 nM, Table 1 ) is a weaker STS inhibitor than its bromo congener 16 (IC 50(P.M.) = 1.65 nM and IC 50(MCF-7) = 0.11 nM, Table 1) suggests that steric hindrance rendered by the bulkier iodine atom of 17 interferes with the binding of its sulfamate group to the catalytic site, preventing the inhibitor from inactivating the enzyme effectively. Hence, for derivatives of EMATE substituted at the 2-position with a halogen, it appears that having a bromine atom is most optimized for STS inhibition and binding of the inhibitor to STS active site. It is worth noting that a recent study carried out by Lu et al. 43 provides evidence for weak halogen-oxygen bonding between halogenated ligands and protein kinases, with the strength of the interactions calculated decreases in the order H ≈ I > Br > Cl. Although it is much weaker than hydrogen bonding, the authors argue that halogen-bonding may play an important role in inhibitor recognition and binding. With reference to our work here, it is not clear whether halogen-oxygen bonding plays a role in the binding of halogenated EMATEs to the STS active site.
Biological Results and Discussion
While brominating EMATE at the 2-position results in a highly potent STS inhibitor 16, substitution of EMATE at the 4-position with a bromine atom is detrimental to activity. As shown in Table 2 , the IC 50 values of the isomer 4-bromoEMATE (19) against STS in placental microsomes (1200 nM) and MCF-7 cells (42 nM) are a few orders of magnitude lower than those of EMATE (IC 50(P.M.) = 18 nM and IC 50(MCF-7) = 0.83 nM) and 16 (IC 50(P.M.) = 1.65 nM and IC 50(MCF-7) = 0.11 nM). Given the electron-withdrawing effect of the bromine atom in 16 and 19 is expected to be similar, it is possible that any beneficial interaction provided by a bromine atom is better recognized by the enzyme active site when it is substituted at the 2-position of EMATE.
In placental microsomes, the IC 50 value observed for 20 (17-deoxyEMATE, IC 50 = 199 nM, Table 2 ) is 11-fold higher than that of EMATE (IC50 = 18 nM, Table 2 ). Hence, removal of the 17-carbonyl group of EMATE significantly reduces STS inhibitory activity, demonstrating an important role for hydrogen bonding between the D-ring of steroidal inhibitor and the active site. However, not all disruptions made to the D-ring of EMATE are detrimental. Previous work has shown that 3-sulfamoyloxy-16,17-seco-estra-1,3,5(10)-triene-16,17-imide, a steroid-like derivative of EMATE, is equipotent to EMATE as an STS inhibitor. 11 As shown in Table 1 , all derivatives of EMATE substituted at the 2-and/or 4-positions with an aliphatic group are weak STS inhibitors. However, substitution of 2-propenyl or n-propyl group at the 2-position is better tolerated by the enzyme than that at the 4-position as shown by the higher inhibitory activity observed for 4 (IC 50(P.M.) = 2500 nM and IC 50(MCF-7) = 37 nM) and 9 (IC 50(P.M.) = 2900 nM and IC 50(MCF-7) = 236 nM) than 5 (IC 50(P.M.) = 9000 nM and IC 50(MCF-7) = 153 nM) and 10 (IC 50(P.M. and MCF-7) s: >10,000 nM). One possible reason for this difference in activity between 2-and 4-alkylated derivatives is the steric hindrance exerted by the hydrogen atom(s) at the neighboring C6 atom on the substituent at the 4-position, restricting the rotation of alkyl groups and hence making them less tolerated by the enzyme. When considering substitution made at either the 2-or 4-positon alone, apparently there is no significant difference in the inhibitory activities observed between the more rigid 2-propenyl group and the more flexible n-propyl group (4 vs 9, and 5 vs 10), suggesting that both groups are not well tolerated by the enzyme active site. Clearly, the steric hindrance poses by these groups is expected to be even more prominent when they are substituted at both the 2-and 4-positions of EMATE (8 and 11). The shielding of the sulfamate group from interacting effectively with the catalytic site of the enzyme by these aliphatic substituents might explain the overall weak STS inhibitory activity observed for compounds 4, 5, 8, and 9 -11. It is interesting to note that 2-methylEMATE, a smaller chain relative of 9, was found to be even a weaker STS inhibitor with an IC 50 of over 10,000 nM in a placental microsomes preparation. 28 Despite a methyl group often being viewed to be isosteric and isolipophilic with the chlorine atom, 44 which means steric hindrance might not be the main detrimental factor, the hyperconjugative electron-donating effect of the methyl group of 2-methylEMATE on the A-ring, as reflected by the calculated pK a of 10.31 for 2-methylphenol, might render the sulfamate group less effective in inactivating STS via sulfamoylation. The best 2-alkyl derivative of EMATE reported to date as an inhibitor of STS is 2-ethylEMATE. Its IC 50 in a placental microsomes preparation was found to be 820 nM. 45 We postulated in previous work several mechanisms through which an aryl sulfamate (eg. EMATE) might inhibit STS. 7, 40 Two of which are i) nucleophilic attack on the sulfur atom of the sulfamoyl group by the hydrated form of formylglycine residue (gem-diol) in the STS active site; and ii) specific or non-specific sulfamoylation by an aryl sulfamate of an essential nucleophilic amino acid residue in the STS active site. Andersen et al. 23, 24 reported that some 1,2,3-benzoxathiazole 2,2-dioxides (e.g. 22 and 23, Figure 2 ) are reactive toward nucleophiles. When the candidate was 3-tosyl-1,2,3-benzoxathiazole 2,2-dioxides (22), hydroxide ion and amines attacked the endocyclic sulfur atom of cyclic sulfamate, resulting in ring opening. Given this observation, we prepared the cyclic sulfamate derivatives of EMATE, 19, 20 and 21 (Scheme 6). The rationale is that if a nucleophilic residue in the enzyme active site attacks the sulfur atom of cyclic sulfamate, these cyclic sulfamates might exhibit STS inhibitory activities. In contrast to acyclic sulfamates like EMATE, where we expect the parent phenol to be released upon sulfamoylation of the enzyme by the sulfamate group, there (23) should be no release of estrone expected for cyclic sulfamates 19, 20 and 21 upon ring opening as their steroid skeleton should remain attached to the sulfamoyl group via its N-atom. Unfortunately, as shown in Table 2 , none of these cyclic sulfamates was found to be active against STS. It is possible that the cyclic sulfamate moiety of 19, 20 and 21 did not bind or align in a similar manner to the sulfamate group of EMATE in the catalytic site of STS for potential attack by a nucleophilic amino acid. Alternatively, the lack of an unsubstituted sulfamate group in 19, 20 and 21 might be the culprit, as it has been shown earlier that a free sulfamate group (H 2 NSO 2 OAr) is prerequisite for potent irreversible inhibition of STS. 10, 41, 46 
Conclusions
A series of 2-and/or 4-substituted derivatives of EMATE was prepared and its 17-carbonyl group removed. The following general order of potency against STS is observed:
The general SAR derived from the studies indicates that EMATE derivatives that have electron-withdrawing substituents (4-nitro, 2-halogens and 2-cyano) on the A-ring, show a higher STS inhibition than EMATE in vitro, with the exception of having a nitro group at the 2-position which results in a significant lowering in potency. This reinforces the relationship between the pK a value/leaving group ability of a parent phenol and the potential of an aryl sulfamate in the inactivation of STS, presumably through sulfamoylation of an essential amino acid residue. The introduction of a bromine at the 4-position of or removal of the 17-carbonyl group of EMATE is detrimental to activity. The derivatives resulted are significantly weaker STS inhibitors than EMATE. When the 2-and/or 4-positions of the Aring are substituted with the bulkier 2-propenyl or 2-n-propyl groups, the potent STS inhibition shown by EMATE is significantly reduced or abolished. For an aryl sulfamate to be effective as an STS inhibitor, inter alia, its sulfamate group must be presented to the catalytic site of the enzyme unhindered and the required interactions with various key amino acid residues in the active site uninterrupted. Three cyclic sulfamates prepared are not STS inhibitors as hoped. This further confirms that a free or N-unsubstituted sulfamate group (H 2 NSO 2 O-) is a prerequisite for potent and irreversible inhibition of STS as shown by inhibitors like EMATE and Irosustat.
Experimental

General
All chemicals were purchased from either Aldrich Chemical Co. (Gillingham, UK) or Lancaster Synthesis (Morecombe, Lancashire, UK). All organic solvents of A.R. grade were supplied by Fisher Scientific (Loughborough, UK). Anhydrous N,N-dimethylformamide (DMF), dichloromethane and pyridine were purchased from Aldrich. Sulfamoyl chloride was prepared by an adaptation of the method of Appel and Berger 47 and was stored as a solution under N 2 in toluene as described by Woo et al. 48 Thin layer chromatography (TLC) was performed on precoated plates (Merck TLC aluminium sheets silica gel 60 F 254 , Art. No. 5554). Product(s) and starting material were detected by viewing under UV light and/or treating with a methanolic solution of phosphomolybdic acid followed by heating. Flash column chromatography was performed using gradient elution (solvents indicated in text) on wet-packed silica gel (Sorbsil C60). IR spectra were determined by a Perkin-Elmer 782 infrared spectrophotometer, and peak positions are expressed in cm -1 . 1 H, 13 C and 19 F NMR spectra were recorded with either a Jeol Delta 270 MHz or a Varian Mercury VX 400 MHz spectrometer.
Chemical shifts are reported in parts per million (ppm, ) relative to tetramethylsilane (TMS) as an internal standard. Coupling constants J are given in Hz. Mass spectra were recorded at the Mass spectrometry Service Center, University of Bath. FAB mass spectra were measured using m-nitrobenzyl alcohol as the matrix. Elemental analyses were performed by the Microanalysis Service, University of Bath. Melting points were determined using a Reichert-Jung Thermo Galen Kofler block and are uncorrected. HPLC was undertaken using a Waters 717 machine with Autosampler and PDA detector. The column used, conditions of elution and purity of sample are as indicated for each compound analysed.
Biology
Assays were performed essentially as described previously. 49 The ability of the compounds synthesized to inhibit STS activity was examined using placental microsomal preparations. Placental microsomes (100,000 g fraction) were prepared from a sulfatasepositive human placenta from a normal-term pregnancy. 50 To determine the IC 50 s for the inhibition of STS, activity was measured in the presence of the inhibitor (0.1 nM-10 M) using Intact monolayers of MCF-7 breast cancer cells were incubated for 20 h at 37 °C with [ 3 H]E1S (5 pmol, 7 x 10 5 dpm, 60 Ci/mmol, NEN Du Pont, Boston, MA) in serum-free minimal essential medium (2.5 mL) with or without inhibitors (0.1-10 µM). After incubation, medium (1 mL) was removed and product estrone separated from E1S by solvent partition using toluene (4 mL). [ 14 C]Estrone (7 x 10 3 dpm, 52 mCi/mmol. Amersham International, U.K.) was used to correct for procedural losses. An aliquot of the organic phase was added to scintillation fluid and the 3 H and 14 C content measured by scintillation spectrometry. The mass of E1S hydrolyzed was calculated from the 3 H counts detected (corrected for the volume of medium and organic solvent used and for recovery of 14 C counts) and the specific activity of the substrate.
Syntheses
2-Nitroestrone (1a) and 4-Nitroestrone (2a)
These were prepared according to the method as described by Tomson and Horwitz 17 .
2-Nitroestrone 3-O-sulfamate (1)
To a solution of 1a (2.50 g, 7.94 mmol) in anhydrous DMF (100 mL) at ice/water temperature and under an atmosphere of nitrogen was added sodium hydride (60% dispersion in mineral oil, 350 mg, 8.73 mmol). After the evolution of hydrogen had ceased, sulfamoyl chloride in toluene (ca. 0.68M, 18 mL) was introduced and the resulting mixture was stirred at room temperature for 3 h. The reaction mixture was then concentrated in vacuo and the resulting residue in ethyl acetate (200 mL) was washed with hydrochloric acid (0.1M, 150 mL) and then brine (4 x 100 mL). After drying (MgSO 4 nm, t R = 3.82 min.
3-O-(2-Propenyl)estrone (3)
To a solution of estrone (10.0 g, 36.98 mmol) in DMF (70 mL) at ice/water temperature was treated cautiously with sodium hydride in portions (60% in mineral oil, 1.63 g, 40.68 mmol). The resulting mixture was heated with 3-bromoprop-1-ene (3.9 mL, 44.38 mmol) at 80 o C for 2 h and then stirred under an atmosphere of nitrogen at room temperature overnight. The reaction mixture was concentrated in vacuo and the resulting slurry diluted with ethyl acetate (300 mL). The organic layer was washed with brine (4 x 100 mL), dried (MgSO 4 ) and evaporated to give a yellow residue. Upon recrystallization of this crude product from hot absolute alcohol, 3 was obtained as pale yellow crystals (9.48 g, 30.54 mmol, 83% 
2,4-Di-(2-propenyl)estrone (8a)
To a solution of a mixture of 4a and 5a (3.14 g, 10.11 mmol) in DMF (20 mL) at ice/water temperature was added cautiously sodium hydride (60% in mineral oil, 485 mg, 12.14 mmol). The resulting mixture was heated with 3-bromoprop-1-ene (1.05 mL, 12.14 mmol) at 80 o C for 2 h and then stirred under an atmosphere of nitrogen at room temperature overnight. The reaction mixture was diluted with ethyl acetate (300 mL) and the organic layer separated was washed with brine (300 mL, 4 x 100 mL), dried (MgSO 4 ) and evaporated to give a brown syrup (3.63 g). The Claisen rearrangement of this mixture of 2-(2-propenyl)estrone-3-O-(2-propenyl) ether (6) and 4-(2-propenyl)estrone-3-O-(2-propenyl) ether (7) was carried out according to the method as described by Patton. 19 The crude 8a that obtained was fractionated by flash chromatography (silica 200 g; ethyl acetate/hexane, 1:3 to 1:2 gradient). The third fraction that collected gave a light brown residue which upon recrystallization from hot cyclohexane yielded 8a as creamy barshaped crystals (2.64 g, 7.53 mmol, 75% (8) This was prepared from 8a (1.0 g, 2.85 mmol) in a similar manner to the sulfamoylaton of 1a. The crude product that obtained was fractionated by flash chromatography (ethyl acetate/hexane, 1:2) to give 8 as fluffy pale yellow residue (722 mg, 1.68 mmol, 59% 
2,4-Di-(2-propenyl)estrone 3-O-sulfamate
2-n-Propylestrone 3-O-sulfamate (9)
To a solution of 4 (250 mg, 642 mol) in absolute ethanol (50 mL) was added a suspension of Pd-C (10%, 250 mg) in absolute ethanol (2 mL) and the resulting suspension was stirred at room temperature overnight under an atmosphere of hydrogen at 50 psi. After removal of the supported catalyst by filtration and evaporation of the filtrate, the crude product obtained was fractionated by flash chromatography (ethyl acetate/hexane, 1:4 to 2:1 gradient) to give 9 as fluffy light yellow residue (220 mg, 562 mol, 88% (10) This was prepared from 5 (250 mg, 481 mol, contained ca. 25% of 4) in a similar manner to the preparation of 9. The crude product that obtained was fractionated by flash chromatography (ethyl acetate/hexane, 1:4 to 1:1 gradient) and the second fraction that isolated gave a mixture of 10 and 9 (ca. 
4-n-Propylestrone 3-O-sulfamate
3:1) as creamy residue (234 mg
2-Fluoroestrone acetate (12a)
This was prepared according to the method as described by Page et al. 20 
2-Fluoroestrone (12b)
2-Fluoroestrone-3-O-sulfamate (12)
To a stirred solution of 12b (65 mg, 230 mol) in anhydrous DMF (7 mL) under an atmosphere of nitrogen was added at room temperature 2,6-di-tert-butyl-4-methylpyridine (139 mg, 0.68 mmol) then a solution of sulfamoyl chloride (0.68M in toluene, 1.61 mL, 1.13 mmol) via a syringe. After stirring the reaction mixture at room temperature for 18 h, ethyl acetate (60 mL) was added and the organic layer separated was washed with brine (3 x 50 mL), dried (MgSO 4 
Estrone acetate (13)
This was prepared from estrone according to the method as described by Page et al. 20 
2-Chloroestrone acetate (15a)
This was prepared according to the method as described by Page et al. 20 To a solution of 13 (500 mg, 1.60 mmol) in trifluoroacetic acid (TFA, 20 mL) was added thallic trifluoroacetate (1.74 g, 3.21 mmol) was and the resulting mixture was stirred at 0 o C under nitrogen for 24 h. Upon removal of TFA under reduced pressure at < 40 o C, the crystalline estrone-thallium (III) complex (14) that obtained was washed twice with 1,2-dichloroethane. 1,4-Dioxane (10 mL) and copper chloride (475 mg, 4.80 mmol) were then added to this washed complex and the resulting mixture was heated under reflux for 3 h. Upon cooling and evaporation of solvent, the residue that obtained was treated with water (30 mL) and the organic components were extracted into dichloromethane (3 x 50 mL). The combined organic extracts were washed with water, dried (MgSO 4 ), filtered and evaporated. The crude product that obtained was fractionated by flash chromatography (ethyl acetate/hexane, 1:4) and the pale yellow solid that obtained (526 mg) was further purified by recrystallization from methanol to give 15a as white crystals (436 mg, 78% 1H, s, C1H ).
2-Chloroestrone (15b)
This was prepared according to the method as described by Page et al. 20 A mixture of 15a (400 mg, 1.15 mmol), K 2 CO 3 (800mg, 5.80 mmol) in MeOH (20 mL) was heated under reflux for 3 h. Upon cooling and evaporation of the solvent, water (20 mL) was added to the residue that obtained and the crude product was extracted into dichloromethane (3 x 20 mL). The combined organic extracts were washed with water, dried (MgSO 4 ), filtered and evaporated to give a yellow crude product which was purified by recrystallization from methanol to give 15b as white crystals (320 mg, 90% (96/4) isocratic; flow rate, 1 mL/min; t R = 2.01 min; purity: 98%.
2-Bromoestrone acetate (16a)
This was prepared from 13 (2.0 g, 6.40 mmol) in the same manner as the preparation of 15a except that copper bromide (8.58 g, 38.41 mmol) was used. The crude product obtained was fractionated by flash chromatography (ethyl acetate/hexane, 1:4) and the pale white solid that isolated (2.05 g) was further purified by recrystallization from methanol to give 16a as colorless crystals (1.79 g, 4.58 mmol, 72% 
2-Bromoestrone (16b)
This was prepared from 16a (1.5 g, 3.83 mmol) in the same manner as the preparation of its chloro analogue 15b. The pale yellow crude product (1.3 g) obtained was purified by recrystallization from ethyl acetate/petroleum ether 60-80 o C (3:2) to give 16b as pale yellow crystals (1.23 g, 3.52 mmol, 92%). o C [Lit. 
2-Bromoestrone 3-O-sulfamate (16)
This was prepared from 16b (500 mg, 1.43 mmol) in a similar manner to the sulfamoylation of 1a. The crude product (620 mg) obtained was fractionated by flash chromatography (chloroform/acetone, 8:1). The beige residue obtained (510 mg) was further purified by recrystallization from acetone/hexane (1:2) to give 16 as beige crystals (405 mg Waters "Symmetry" C18 (packing: 3.5 m, 4.6 x 150 mm); mobile phase MeCN/H 2 O (90/10) isocratic; flow rate, 1 mL/min; t R = 2.19 min; purity: 98%.
2-Iodoestrone acetate (17a)
This was prepared from 13 (5.0 g, 16.01 mmol) in the same manner as the preparation of 15a except that copper iodide (18.29 g, 96.03 mmol) was used. The crude product obtained was purified by flash chromatography with ethyl acetate/hexane (1:4) and the yellow solid obtained (6.25 g) was further purified by recrystallization from methanol to give 17a as pale yellow crystals 
2-Iodoestrone (17b)
This was prepared from 17a (4.0 g, 9.13 mmol) in the same manner as the preparation of its chloro analogue 15b. The yellow crude product obtained was recrystallized from methanol to give 17b as pale yellow crystals (3.29 g, 91% 
2-Iodoestrone 3-O-sulfamate (17)
This was prepared from 17b (500 mg, 1.26 mmol) in a similar manner to the sulfamoylation of 1a. The crude product obtained was fractionated by flash chromatography (chloroform/acetone, 8:1) and the beige residue that collected (450 mg) was further purified by recrystallization from acetone/hexane (1:2) to give 17 as beige crystals (342 mg, 57% 
2-Cyanoestrone (18b)
2-Cyanoestrone acetate (18a) was prepared from 13 (500 mg, 1.60 mmol) in the same manner as the preparation of 15a except that the estrone-thallium (III) complex was heated with copper cyanide in pyridine instead. Without the isolation of product, crude 18a obtained was directly deacetylated in the same manner as the preparation of its chloro analogue 15b. Upon fractionation of crude 18b by flash chromatography (ethyl acetate/hexane, 1:4), the pale yellow solid obtained (286 mg) was further purified by recrystallization from methanol to give 18b as white crystals (260 mg, 80% Waters "Symmetry" C18 (packing: 3.5 m, 4.6 x 150 mm); mobile phase MeCN/H 2 O (70/30) isocratic; flow rate, 1 mL/min; t R = 1.12 min; purity: 94%.
4-Bromoestrone (19a)
To 300 mL of glacial acetic acid was added estrone (1.0 g, 3.70 mmol) and the suspension was gently heated with stirring until it became a solution. Upon cooling to ice-water temperature, powdered iron (10-15 mg) was added to the stirred solution, followed by a dropwise addition of a 5% v/v solution of bromine in glacial acetic acid until the reaction mixture no longer decolorized the added bromine. After stirring for an additional 5 min, the reaction mixture was poured into ice and water. The precipitate that formed was collected by filtration, washed with water and recrystallized from 98% ethanol to give 19a as white powder (300 mg, 858 mol, 23% 
3-Hydroxy-1,3,5(10)-estratriene (20a)
This was prepared by heating a mixture of estrone (10.0 g, 36.98 mmol), hydrazine monohydrate (15 mL, mmol), potassium hydroxide (15 g, mmol) in ethanol (5 mL) and diethylene glycol (120 ml) under the conditions for a Wolff-Kishner reduction of steroid ketones. The crude product obtained was purified by flash chromatography (ethyl acetate/hexane, 1:4) to give 20a (7.0 g, 65% 
1,3,5(10)-Estratriene 3-O-sulfamate (20)
This was prepared from 20a (1.0 g, 3.90 mmol) in a similar manner to the sulfamoylation of 1a. The crude product obtained was fractionated by flash chromatography (ethyl acetate/hexane, 1:3) and the second fraction that collected (911 mg, 69%) was recrystallized from chloroform/hexane (6:7) to give a crop of 20 as white crystals (280 mg 
2-Aminoestrone (21a)
To a solution of 1a (1.0 g, 3.17 mmol) in dichloromethane (50 mL) was added a suspension of Pd-C (10%, 200 mg) in dichloromethane (3 mL). The resulting suspension was stirred at room temperature under an atmosphere of hydrogen (balloon) for 20 h at which time the reduction was complete according to TLC. After removal of the supported catalyst by filtration and evaporation of filtrate, the crude product that obtained (940 mg) [R f (chloroform/acetone, 4:1) 0.31, c.f. R f 0.76 (1a)] was used for the next reaction without further purification.
2-Tosylamidoestrone (21b)
To a stirred suspension of the freshly prepared crude 21a (900 mg, 3.15 mmol) in anhydrous dichloromethane (30 mL) at ice/water temperature was added anhydrous pyridine (0.5 mL) followed by tosyl chloride (605 mg, 3.17 mmol). After stirring at room temperature for 3 h, the reaction mixture was filtered and the filtrate thus obtained was diluted with ethyl acetate (50 mL). The organic layer was washed with hydrochloric acid (1M, 2 x 50 mL) followed by brine (4 x 50 mL), dried (MgSO 4 ), filtered and evaporated to give a yellow residue (1.23 g). This was recrystallized from ethyl acetate/hexane (4:3) to give a crop of slightly impure 21b as fine bright yellow crystals (390 mg). The yellow residue (720 mg) that obtained from the evaporation of the mother liquor was fractionated by flash chromatography (ethyl acetate/hexane, 1:2 to 4:1 gradient). The third fraction that obtained gave a white residue (568 mg) which was recrystallized from ethyl acetate/hexane (2:3) to give 21b as soft creamy Sulfuryl chloride (1.40 mL of a 0.5 M solution in dichloromethane, 700 mol) was added dropwise over a 5 min period to a stirred mixture of 21b (280 mg, 637 mol) and triethylamine (0.27 mL, 1.911 mmol) in dichloromethane (10 mL) at -78 o C under an atmosphere of nitrogen. After an additional 15 min, the reaction mixture was allowed to warm to room temperature, concentrated and the yellow residue that obtained was dissolved in ethyl acetate (50 mL). The organic layer was washed with hydrochloric acid (1M, 50 mL) followed by brine (4 x 50 mL), dried (MgSO 4 ), filtered and evaporated to give a yellow residue (390 mg) which was fractionated by flash chromatography (chloroform/acetone, 16:1). The first fraction that isolated upon evaporation gave the product (192 mg, 383 mol, 60%) which was recrystallized from ethyl acetate/hexane to give 21c as white crystals (90 mg 
4-Aminoestrone (23a)
To a solution of 2a (1.49 g, 4.73 mmol) in tetrahydrofuran (THF, 80 mL) was added a suspension of Pd-C (10%, 300 mg) in THF (2 mL) and the resulting suspension was stirred at room temperature under an atmosphere of hydrogen (balloon) for 20 h. After removal of the supported catalyst by filtration and evaporation of filtrate, the crude product that obtained (1.42 g) [R f chloroform/acetone, 4:1) 0.53, c.f. R f 0.68 (2a)] was used for the next reaction without further purification.
4-Tosylamidoestrone (23b)
To a stirred suspension of the freshly prepared crude 23a (500 mg, 1.75 mmol) in anhydrous dichloromethane (15 mL) at ice/water temperature was added anhydrous pyridine (0.28 mL) followed by tosyl chloride (334 mg, 1.75 mmol). After stirring at room temperature for 3 h, the reaction mixture was diluted with ethyl acetate (100 mL). The organic layer was washed with hydrochloric acid (1M, 50 mL) followed by brine (4 x 50 mL), dried (MgSO 4 ), filtered and evaporated to give a yellow residue (790 mg) which was fractionated by flash chromatography (ethyl acetate/hexane, 1:1 to 2:1 gradient). The major fractions that isolated gave a light yellow residue (670 mg) and this was recrystallized from acetone/diethyl ether ( Sulfuryl chloride (2.0 mL of a 0.5 M solution in dichloromethane, 1.00 mmol) was added dropwise with stirring over a 5 min period to 23b (400 mg, 910 mol) and triethylamine (0.39 mL, 2.73 mmol) in dichloromethane (20 mL) at ice-water temperature under an atmosphere of nitrogen. After an additional 15 min, the reaction mixture was allowed to warm to room temperature, concentrated and diluted with ethyl acetate (50 mL). The organic layer was washed with hydrochloric acid (1M, 100 mL) followed by brine (4 x 50 mL), dried (MgSO 4 ), filtered and evaporated to give a light yellow residue/syrup (550 mg) which was fractionated by flash chromatography (chloroform/acetone, 16:1). The first fraction that isolated upon evaporation gave 23c as a creamy residue (312 mg). mol) in water (5 mL). The resulting mixture was refluxed for 4 h, cooled, concentrated and diluted with ethyl acetate (50 mL). The organic layer was washed with hydrochloric acid (1M, 50 mL) followed by brine (4 x 50 mL). After drying (MgSO 4 ) and filtration, the filtrate on evaporation gave a yellow-green syrup (170 mg) which was fractionated by flash chromatography (ethyl acetate/hexane, 1:1 to 4:1 gradient) to give a green residue (95 mg). A solution of this fraction in absolute ethanol was heated with activated charcoal and upon filtration and evaporation gave 23 as a creamy powder (85 mg, 245 mol, 82%); IR  max /cm -1 (3H, s, C18H 3 ), 1.2-2.8 (~15H, m) 
